Last reviewed · How we verify
AK117
AK117 is a small molecule targeting the CD47/SIRPα axis.
AK117 is a small molecule targeting the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | AK117 |
|---|---|
| Sponsor | Akeso |
| Drug class | CD47/SIRPα axis inhibitor |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AK117 works by binding to CD47 and blocking its interaction with SIRPα on the surface of myeloid cells, thereby preventing immune suppression and enhancing anti-tumor immune responses.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer (PHASE2)
- A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors (PHASE1, PHASE2)
- A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer (PHASE3)
- A Study of AK112 in Advanced Malignant Tumors (PHASE1, PHASE2)
- Ligufalimab and Cadonilimab in Advanced Liver Cancers (PHASE2)
- Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN (PHASE3)
- A Study of Ivonescimab in First-Line ES-SCLC (PHASE2)
- A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK117 CI brief — competitive landscape report
- AK117 updates RSS · CI watch RSS
- Akeso portfolio CI